Agenus Inc (AGEN) stock
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.40+0.19 (+3.06%)
Close on Nov 18, 2026Market cap $288.13MP/E –Yield –
Agenus operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Agenus's operating cash flow for the twelve months ending Jun 30, 2026 was -$98.50M. For fiscal 2025 it was -$77.20M. The highest annual figure on record is $10.15M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$77.20M | – |
| FY2024 | Dec 31, 2024 | -$158.32M | – |
| FY2023 | Dec 31, 2023 | -$224.20M | – |
| FY2022 | Dec 31, 2022 | -$175.37M | -1828.7% |
| FY2021 | Dec 31, 2021 | $10.15M | – |
| FY2020 | Dec 31, 2020 | -$139.10M | – |
| FY2019 | Dec 31, 2019 | -$18.68M | – |
| FY2018 | Dec 31, 2018 | -$131.10M | – |
| FY2017 | Dec 31, 2017 | -$94.23M | – |
| FY2016 | Dec 31, 2016 | -$79.96M | – |
| FY2015 | Dec 31, 2015 | -$47.18M | – |
| FY2014 | Dec 31, 2014 | -$38.23M | – |
| FY2013 | Dec 31, 2013 | -$19.53M | -2029.0% |
| FY2012 | Dec 31, 2012 | $1.01M | – |
| FY2011 | Dec 31, 2011 | -$16.25M | – |
| FY2010 | Dec 31, 2010 | -$14.76M | – |
| FY2009 | Dec 31, 2009 | -$24.19M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$53.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$65.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$60.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$58.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$47.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.19M | -124.5% |
| Q2 FY2022 | Jun 30, 2022 | -$43.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$52.39M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.93M | – |
| Q3 FY2021 | Sep 30, 2021 | $131.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.59M | – |
| Q3 FY2020 | Sep 30, 2020 | -$31.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.38M | -191.4% |
| Q1 FY2020 | Mar 31, 2020 | -$34.51M | -145.1% |
| Q4 FY2019 | Dec 31, 2019 | -$31.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.79M | – |
| Q2 FY2019 | Jun 30, 2019 | $40.90M | – |
| Q1 FY2019 | Mar 31, 2019 | $76.59M | – |
| Q4 FY2018 | Dec 31, 2018 | -$35.80M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$30.50M | – |
| Q1 FY2018 | Mar 31, 2018 | -$40.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$25.80M | -261.3% |
| Q3 FY2017 | Sep 30, 2017 | -$26.20M | -210.1% |
| Q2 FY2017 | Jun 30, 2017 | -$27.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.83M | – |
| Q4 FY2016 | Dec 31, 2016 | $16.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $23.80M | – |
See a number that looks wrong?